The risk of clinical progression for human immunodeficiency virus (HIV)-infected persons receiving treatment with highly active antiretroviral therapy (HAART) is poorly defined. From an inception cohort of 8457 HIV-infected persons, 2027 patients who started HAART during prospective follow-up were examined. Results were validated in another 2 groups of patients (n = 1946 and n = 1442). In total, 200 patients (9.9%) experienced clinical progression during 5177 person-years (incidence, 3.9/100 years). The most recently measured CD4 cell count, virus load, and hemoglobin level all were independently related to the risk of clinical progression, as was a diagnosis of severe AIDS before the start of HAART. On the basis of these findings, a scoring system was derived (range, 0-17). A single unit increase in the score was associated with a 38% increased risk of clinical progression (relative hazard, 1.38; 95% confidence interval, 1.33-1.43; P < .0001). The scoring system was validated with remarkably good agreement in the 2 other cohorts. This system can be used in patient and resource management.
Lundgren, JD. ; Mocroft, A. ; Gatell, JM. ; Ledergerber, B. ; Monforte, AD ; et. al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study.40th Interscience Conference on Antimicrobial Agents and Chemotherapy (TORONTO(Canada), Sep 17-21, 2000). In: The Journal of Infectious Diseases, Vol. 185, no. 2, p. 178-187 (2002)
